These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related]
26. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Correll CU; Leucht S; Kane JM Am J Psychiatry; 2004 Mar; 161(3):414-25. PubMed ID: 14992963 [TBL] [Abstract][Full Text] [Related]
27. Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia. Pi EH; Simpson GM Mod Probl Pharmacopsychiatry; 1983; 21():80-6. PubMed ID: 6140635 [No Abstract] [Full Text] [Related]
28. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Lévesque C; Hernandez G; Mahmoudi S; Calon F; Gasparini F; Gomez-Mancilla B; Blanchet PJ; Lévesque D Neuroscience; 2017 Oct; 361():43-57. PubMed ID: 28790021 [TBL] [Abstract][Full Text] [Related]
29. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Quinn N; Marsden CD J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):844-7. PubMed ID: 6236286 [TBL] [Abstract][Full Text] [Related]
30. The effect of dopamine antagonists in spontaneous and tardive dyskinesia. Fog R Psychopharmacology Suppl; 1985; 2():118-21. PubMed ID: 2860655 [TBL] [Abstract][Full Text] [Related]
31. Tardive dyskinesia: a role for the endogenous opioid system. Sandyk R Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480 [TBL] [Abstract][Full Text] [Related]
32. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Allen RM Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548 [TBL] [Abstract][Full Text] [Related]
33. [Use of metoclopramide hydrochloride in patients with residual schizophrenia with tardive dyskinesias]. Kiehl U; Nitzsche M; Fischer GJ Psychiatr Neurol Med Psychol (Leipz); 1985 Dec; 37(12):722-6. PubMed ID: 2869538 [TBL] [Abstract][Full Text] [Related]
34. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Soares-Weiser K; Rathbone J Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425 [TBL] [Abstract][Full Text] [Related]
35. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Chouinard G; Steinberg S Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):571-8. PubMed ID: 6131490 [TBL] [Abstract][Full Text] [Related]
36. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Lublin H; Gerlach J; Hagert U; Meidahl B; Mølbjerg C; Pedersen V; Rendtorff C; Tolvanen E Eur Neuropsychopharmacol; 1991 Dec; 1(4):541-8. PubMed ID: 1822319 [TBL] [Abstract][Full Text] [Related]